Retatrutide (LY3437943) is a triple-agonist peptide evaluated across GLP-1, GIP, and glucagon pathways. It is used in metabolic research focused on appetite regulation, energy expenditure, and glycaemic control.

What It Is

• GLP-1 pathway: Appetite and satiety signalling models
• GIP pathway: Insulin and nutrient utilisation models
• Glucagon pathway: Energy expenditure and fat metabolism models

How It Works

Retatrutide is studied for combined metabolic pathway activity that may support:

• Reduced appetite signalling
• Improved glucose regulation markers
• Increased energy expenditure
• Enhanced fat-oxidation activity

Its long-acting profile supports a once-weekly reference cadence.

Product Specifications

Reconstitution

Add 2 mL bacteriostatic water to the vial.

Final concentration: 10 mg ÷ 2 mL = 5 mg/mL

• Introduce diluent slowly down the vial wall
• Gently swirl until fully dissolved
• Do not shake

Dosing Reference (mg-Based – Insulin Syringe)

Insulin syringe conversion: 1 unit = 0.01 mL
At 5 mg/mL: 1 unit = 0.05 mg

Weekly Example Structure

Suggested increase approach: Increase weekly dosage gradually based on metabolic response. Remain at each weekly level for 4 weeks before increasing to the next level.

Expected Outcomes (Research Context)

• Reduced appetite signalling
• Increased energy expenditure
• Improved glucose markers
• Enhanced fat-oxidation pathway activity

What’s in the Box

• 1 × Retatrutide 10 mg lyophilised vial
• 1 × 2 mL bacteriostatic water

Storage

• Lyophilised: Store dry and protected from light
• After reconstitution: Store at 2–8 °C and use within 30 days

EU Pharmaceuticals

EU Pharmaceuticals supplies analytically verified peptides tested for identity, purity, and stability. Each lot is validated via HPLC and mass spectrometry for consistent research-grade quality.

For laboratory and research use only. Not for human or veterinary use.